Why the research makes the clinician.
Mechanistic depth in cancer biology and immunology is not a credential — it is a clinical asset. Understanding the tumor-immune interface at the molecular level changes how oncology is practiced: what questions get asked on rounds, how trial eligibility is evaluated, and how treatment resistance is interpreted.
Research highlights. Postdoctoral work at HMS/MGH included cancer-associated fibroblast biology in pancreatic ductal adenocarcinoma and immune-epithelial interactions in patient-derived pulmonary organoid systems. Doctoral research focused on miRNA-15a/16-1 regulation of T-cell biology. Earlier Wyss/HMS work supported biomaterial vaccine platforms.